Maria Zannes's most recent trade in BioAffinity Technologies Inc was a trade of 37,037 Common Stock done . Disclosure was reported to the exchange on Jan. 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioAffinity Technologies Inc | Maria Zannes | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 37,037 | 280,359 | - | 0 | Common Stock | |
| BioAffinity Technologies Inc | Maria Zannes | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 33,784 | 243,322 | - | 0 | Common Stock | |
| BioAffinity Technologies Inc | Maria Zannes | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 8,296 | 209,538 | - | 0 | Common Stock | |
| BioAffinity Technologies Inc | Maria Zannes | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 64,848 | 0 | - | - | Stock Option (right to buy) | |
| BioAffinity Technologies Inc | Maria Zannes | President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. | 08 Apr 2024 | 64,848 | 229,506 | - | 1.2 | 75,224 | Common Stock |
| BioAffinity Technologies Inc | Maria Zannes | President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.65 per share. | 08 Apr 2024 | 28,264 | 201,242 | - | 2.7 | 74,900 | Common Stock |
| BioAffinity Technologies Inc | Zannes Maria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 23,885 | 164,658 | - | 0 | Common Stock | |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 1.48 per share. | 01 Oct 2023 | 12,668 | 140,773 | - | 1.5 | 18,749 | Common Stock |
| BioAffinity Technologies Inc | Zannes Maria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 1.58 per share. | 01 Oct 2023 | 11,867 | 128,105 | - | 1.6 | 18,750 | Common Stock |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 1.91 per share. | 01 Jan 2023 | 26,178 | 105,993 | - | 1.9 | 50,000 | Common Stock |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 1.83 per share. | 01 Jan 2023 | 10,245 | 116,238 | - | 1.8 | 18,748 | Common Stock |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 1.89 per share. | 01 Jan 2023 | 9,920 | 79,815 | - | 1.9 | 18,749 | Common Stock |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 2.28 per share. | 01 Jan 2023 | 8,227 | 69,895 | - | 2.3 | 18,758 | Common Stock |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | 31 Aug 2022 | 23,672 | 43,569 | - | 4.2 | 99,422 | Common Stock | |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 23,571 | 23,571 | - | - | Warrants (right to buy) | |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 18,099 | 61,668 | - | 0 | Common Stock | |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 Aug 2022 | 16,326 | 16,326 | - | - | Non-tradeable Warrants (right to buy) | |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 Aug 2022 | 16,326 | 16,326 | - | - | Warrants (right to buy) | |
| BioAffinity Technologies Inc | Maria Zannes | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 Aug 2022 | 16,326 | 19,897 | - | - | Common Stock |